NCT02307812 2025-01-09Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in FranceEli Lilly and CompanyApproved for marketing